U.S. Authorities Seek Documents From Troubled Covid Vaccine Manufacturer

Emergent BioSolutions, which ruined 75 million vaccine doses at its Baltimore plant, disclosed records requests from Congress and federal and state law enforcement agencies.

Biotech Company That Botched Vaccines Faces Investor Revolt

In the latest shareholder lawsuit, a pension fund accused executives at Emergent BioSolutions of insider trading. The company, under investigation by Congress, has halted manufacturing of Covid-19 vaccines at its Baltimore factory at regulators’...

Biotech Company That Botched Vaccines Faces Investor Revolt

In the latest shareholder lawsuit, a pension fund accused executives at Emergent BioSolutions of insider trading. The company, under investigation by Congress, has halted manufacturing of Covid-19 vaccines at its Baltimore factory at regulators’...

High Hopes for Johnson & Johnson’s Covid Vaccine Have Fizzled in the U.S.

Production problems and a brief pause on its use kept the one-dose vaccine from becoming the game changer that health officials across the country believed it would be.

Vaccine Maker Earned Record Profits but Delivered Disappointment in Return

Emergent BioSolutions was awarded a $628 million federal contract with no competitive bidding. Top executives received big bonuses while factories mostly sat idle and tens of millions of Covid-19 doses were thrown away.

F.D.A. details failures at a Baltimore plant that led to unusable vaccine doses.

The F.D.A. advised Johnson & Johnson on Friday that it should throw out the equivalent of 60 million doses produced at the Baltimore plant.

F.D.A. Tells Johnson & Johnson That 60 Million Vaccine Doses Cannot Be Used

The agency has not decided whether to allow a troubled vaccine factory in Baltimore to reopen.

First U.S. Vaccine Donations Will Go to ‘Wide Range’ of Nations in Need

Latin America, South and Southeast Asia and Africa will be among the recipients of an initial 25 million excess doses that the Biden administration is sharing this month.